EUCTR2009-013668-38-DK进行中（未招募）不适用
A phase IIb, randomised, double-blind, placebo-controlled, parallel group, safetyand efficacy study of BI 10773 (10 mg and 25 mg) administered orally, once daily over 78 weeks in type 2 diabetic patients receiving treatment with basal insulin (glargine, detemir, or NPH insulin only) with or without concomitant metformin and/or sulfonylurea therapy and insufficient glycaemic control
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 985
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Signed and dated written informed consent by date of Visit 1 in accordance with
- •Good Clinical Practice (GCP) and local legislation
- •Male and female patients with a diagnosis of T2DM treated with basal glargine or
- •detemir insulin (=20 IU/day) or NPH insulin (=14 IU/day) with or without
- •concomitant metformin and / or sulfonylurea. The insulin and oral anti-diabetic
- •therapy has to be unchanged for at least 12 weeks prior to randomization.
- •HbA1c of >7.0% and =10% at Visit 1 (screening)
- •Suitability for trial participation according to investigator's judgment (evaluating all
- •alternative treatment options and in consideration of the patient completing the study)
- •Age =18 years at Visit 1 (screening)
- •BMI =45 kg/m2 (Body Mass Index) at Visit 1 (screening)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Clinical conditions that might interfere with the subject's ability to participate in the trial include, but are not limited to, the following:
- •Uncontrolled hyperglycemia with a glucose level >240 mg/dl (>13.3 mmol/L) after an overnight fast or >400 mg/dl (>22.2 mmol/L) in a randomly performed measurement during placebo run-in and confirmed by a second measurement (not on the same day).
- •Frequent (at the discretion of the investigator) episodes of hypoglycemic events on
- •basal insulin therapy
- •Myocardial infarction, stroke, or Transient Ischemic Attack (TIA) within 3 months
- •prior to obtaining informed consent
- •Impaired hepatic function, defined by serum levels of either ALT (SGPT), AST
- •(SGOT), or alkaline phosphatase (ALP) above 3 times the upper limit of normal
- •ULN) as determined at Visit 1
- •Impaired renal function, defined as GFR <30 ml/min
- •The metformin or sulfonylurea that you’re taking is not being used in accordance with local prescribing information.
- •Any contraindications to the background basal insulin (glargine, detemir, or NPH)
- •according to the local label
- •Known hypersensitivity or allergy to the investigational product BI 10773 or its
- •Treatment with any other oral anti-diabetic medications, other than metformin and / or sulfonylurea therapy, within 3 months of obtaining informed consent
- •Patients with a history of having received chronic short acting insulin, a
- •Glycogen-like peptide – 1 (GLP-1) analogue, or an Amylin agonist, within 3 months
- •of signing informed consent
- •Gastric bypass surgery or any other gastrointestinal surgery that may induce
- •mal-absorption
- •Treatment with anti-obesity drugs (e.g., including but not limited to sibutramine,
- •orlistat, or rimonabant) 3 months prior to informed consent
- •Current treatment with systemic steroids at time of informed consent or change in
- •dosage of thyroid hormones within 6 weeks prior to informed consent
- •Patients with history of any cancer within last 5 years with the exception of basal cell and squamous cell skin cancer
- •Pre-menopausal women (last menstruation =1 year prior to informed consent) who: are nursing their infant or pregnant or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study
- •Alcohol or drug abuse within the 3 months prior to informed consent that would
- •interfere with trial participation
- •Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells (e.g., hemolytic anemia, thalassemias, sickle cell disease, hemochromatosis with routine phlebotomy treatment, malaria). An accurate HbA1c can not be established in patients with hemolysis
- •Participation in another trial with an investigational drug within 2 months prior to
- •informed consent
研究者
相似试验
进行中（未招募）
不适用
A phase IIb, randomised, double-blind, placebo-controlled, parallel group, safetyand efficacy study of BI 10773 (10 mg and 25 mg) administered orally, once daily over 78 weeks in type 2 diabetic patients receiving treatment with basal insulin (glargine, detemir, or NPH insulin only) with or without concomitant metformin and/or sulfonylurea therapy and insufficient glycaemic controlMedDRA version: 12.0Level: LLTClassification code 10067585Term: Type 2 diabetes mellitusType 2 Diabetes MellitusEUCTR2009-013668-38-IEBoehringer Ingelheim Limited985
进行中（未招募）
1 期
A phase IIb, randomised, double-blind, placebo-controlled, parallel group, safetyand efficacy study of BI 10773 (10 mg and 25 mg) administered orally, once daily over 78 weeks in type 2 diabetic patients receiving once-daily treatment with basal insulin (glargine, detemir, or NPH insulin only) with or without concomitant metformin and/or sulfonylurea therapy and insufficient glycaemic controlMedDRA version: 12.0Level: LLTClassification code 10067585Term: Type 2 diabetes mellitusType 2 Diabetes MellitusEUCTR2009-013668-38-FRBoehringer Ingelheim France985
进行中（未招募）
1 期
Efficacy and safety of BI 10773 in combination with insulin in patients with type 2 diabetesMedDRA version: 14.0 Level: PT Classification code 10067585 Term: Type 2 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersType 2 Diabetes MellitusEUCTR2009-013668-38-GBBoehringer Ingelheim Ltd985
进行中（未招募）
不适用
A phase IIb, randomised, double-blind, placebo-controlled, parallel group, safety and efficacy study of BI 10773 (10 mg and 25 mg) administered orally, over 78 weeks in type 2 diabetic patients receiving treatment with basal insulin (glargine, detemir, or NPH insulin only) with or without concomitant metformin and/or sulfonylurea therapy and insufficient glycaemic control.MedDRA version: 14.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 2 Diabetes MellitusEUCTR2009-013668-38-PTBoehringer Ingelheim, Lda985
进行中（未招募）
1 期
A clinical trial to evaluate ZED1227 in comparison with placebo in subjects with celiac disease experiencing symptoms despite gluten-free dietTreatment of celiac diseaseMedDRA version: 20.0Level: LLTClassification code 10007864Term: Celiac diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2020-004612-97-DEDr. Falk Pharma GmbH400